psaizi.com

What It Is

Psaizi is an AI healthcare service for epilepsy management launched by Psaizi Technologies Private Limited. Its core focus is an “At-Home EEG Service” for home-based EEG monitoring and real-time seizure prediction. According to the official website, Psaizi has signed a clinical research collaboration with AIIMS Delhi to validate the clinical effectiveness of its real-time epilepsy prediction algorithm. The goal is to improve epilepsy management and diagnosis while helping patients reduce the burden of frequent hospital visits.

Core Capabilities

The product focuses on real-time EEG data access, an interactive dashboard, remote patient monitoring, and personalized AI predictions. The system reportedly combines daily EEG data with seizure occurrence information to build a personalized AI model for each patient, enabling seizure predictions that are better tailored to individual conditions. A typical use case would be patients completing EEG monitoring at home while doctors remotely review the data through a dashboard, reducing the need for in-person hospital visits.

Pricing and Integrations

The official website does not disclose any pricing, plans, free trial, or insurance/payment information. It also does not state whether the product has received regulatory approval as a medical device. On the technical integration side, it only mentions an interactive dashboard and real-time data access, with no details on APIs, hospital information systems, electronic medical records, or compatibility with specific EEG devices. Data privacy, secure storage, patient consent, and medical compliance terms are also absent from the captured content, which is a significant gap for a medical AI product.

Pros and Cons

The main advantage is that Psaizi targets a clear use case: the long-term monitoring challenges faced by epilepsy patients. The team has backgrounds in AI/ML, digital health, neurobiology, and neurophysiology, and its collaboration with AIIMS Delhi adds credibility to its clinical validation efforts. The limitations are that the website does not publicly provide key metrics such as algorithm accuracy, sample size, false positive rate, false negative rate, or applicable patient boundaries, making it difficult to assess real-world output quality. The contact information also still contains placeholder-style text such as “contact email/phone number,” suggesting that its commercial information remains incomplete.

Who It’s For and Access from China

Psaizi is better suited for epilepsy patient families, neurologists, hospital EEG/epilepsy centers, and clinical research teams interested in further consultation or pilot programs. For users in China, website accessibility, cross-border healthcare service delivery, payment, and local compliance status are all undisclosed, so actual usability remains unknown. If deployed in China, priority should be given to local medical device compliance, hospital system integration, cross-border data transfer, and personal health information protection requirements. Domestic hospital neurophysiological monitoring solutions or compliant telemedicine platforms may also be worth evaluating as alternatives.